Cas 1660119-24-3,benzyl-[2-(4-methyl-piperazin-1-yl)-5-nitro-pyridin-4-yl]-amine

1660119-24-3

Post Buying Request

Basic information

Product Name: benzyl-[2-(4-methyl-piperazin-1-yl)-5-nitro-pyridin-4-yl]-amine
Synonyms: benzyl-[2-(4-methyl-piperazin-1-yl)-5-nitro-pyridin-4-yl]-amine
CAS NO:1660119-24-3
Molecular Formula:
Molecular Weight: 327.386
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: benzyl-[2-(4-methyl-piperazin-1-yl)-5-nitro-pyridin-4-yl]-amine(CAS DataBase Reference)
NIST Chemistry Reference: benzyl-[2-(4-methyl-piperazin-1-yl)-5-nitro-pyridin-4-yl]-amine(1660119-24-3)
EPA Substance Registry System: benzyl-[2-(4-methyl-piperazin-1-yl)-5-nitro-pyridin-4-yl]-amine(1660119-24-3)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1660119-24-3(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1660119-24-3 Suppliers

Recommended suppliers

1660119-24-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1660119-24-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,6,0,1,1 and 9 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1660119-24:
(9*1)+(8*6)+(7*6)+(6*0)+(5*1)+(4*1)+(3*9)+(2*2)+(1*4)=143
143 % 10 = 3
So 1660119-24-3 is a valid CAS Registry Number.

1660119-24-3Upstream product

1660119-24-3Downstream Products

1610045-55-0 N-4-benzyl-6-(4-methyl-piperazin-1-yl)-pyridine-3,4-diamine

1660119-24-3Relevant academic research and scientific papers

COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA

-

Page/Page column 20; 28, (2019/08/12)

The present invention relates to the use of volasertib, or a pharmaceutically acceptable salt thereof or a hydrate thereof, in combination with a BET inhibitor, or a pharmaceutically acceptable salt thereof or a hydrate thereof for treating patients suffering from acute myeloid leukemia (AML).

PYRIDINONES

-

Paragraph 0321; 0322; 0323, (2015/02/25)

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3 and X1 through X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

PYRIDINONES

-

Page/Page column 102; 103, (2015/02/25)

TRIAZOLOPYRAZINE

-

Paragraph 0319 - 0322, (2014/05/25)

Disclosed are compounds of the formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1660119-24-3